Is Goldman Sachs Stock a Buy Sell or Hold?
When the Federal Reserve started hiking rates in 2022, banks’…
Buy
54
AXSM Quote, Financials, Valuation and Earnings
Last price:
$121.95
Seasonality move
:
13.74%
Day range:
$120.52 - $123.47
52-week range:
$64.11 - $139.13
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.14x
P/B ratio:
104.27x
Volume:
432.2K
Avg. volume:
984K
1-year change:
74.81%
Market cap:
$5.9B
Revenue:
$385.7M
EPS (TTM):
-$5.99
Analysts' Opinion
-
Consensus RatingAxsome Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $173.00, Axsome Therapeutics has an estimated upside of 41.91% from its current price of $121.91.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $115.00 representing 100% downside risk from its current price of $121.91.
Fair Value
-
According to the consensus of 12 analysts, Axsome Therapeutics has 41.91% upside to fair value with a price target of $173.00 per share.
AXSM vs. S&P 500
-
Over the past 5 trading days, Axsome Therapeutics has overperformed the S&P 500 by 2.11% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Axsome Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Axsome Therapeutics has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Axsome Therapeutics reported revenues of $118.8M.
Earnings Growth
-
Axsome Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Axsome Therapeutics reported earnings per share of -$1.54.
Enterprise value:
5.8B
EV / Invested capital:
--
Price / LTM sales:
15.14x
EV / EBIT:
--
EV / Revenue:
15.06x
PEG ratio (5yr expected):
-1.34x
EV / Free cash flow:
-45.15x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$352.4M
Return On Assets:
-51.07%
Net Income Margin (TTM):
-74.47%
Return On Equity:
-244.32%
Return On Invested Capital:
-96.73%
Operating Margin:
-51.89%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | $270.6M | $385.7M | $71.5M | $118.8M | |
| Gross Profit | $44.8M | $244.5M | $352.4M | $64.2M | $108.3M | |
| Operating Income | -$176.5M | -$182.9M | -$252.4M | -$55.1M | -$61.6M | |
| EBITDA | -$175.2M | -$225M | -$272.6M | -$96.5M | -$70.5M | |
| Diluted EPS | -$4.57 | -$5.20 | -$5.99 | -$2.08 | -$1.54 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $184M | $86.5M | $245.6M | $504.3M | $485.1M | |
| Total Assets | $186.1M | $87.8M | $331.5M | $588.2M | $568.5M | |
| Current Liabilities | $23.4M | $23.1M | $96.6M | $138.9M | $230.1M | |
| Total Liabilities | $72.3M | $72.2M | $221.9M | $397.3M | $511.5M | |
| Total Equity | $113.8M | $15.6M | $109.6M | $191M | $57M | |
| Total Debt | -- | -- | $94.3M | $178.1M | $180.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$116.5M | -$145.1M | -$128.4M | -$30.4M | -$26.2M | |
| Cash From Investing | -$53.7M | -$582K | -$270K | -$7K | -$30K | |
| Cash From Financing | $284.6M | $331M | $57.8M | -$2K | $14.2M | |
| Free Cash Flow | -$117.2M | -$145.7M | -$128.7M | -$30.4M | -$26.2M | |
AXSM
Sector
Market Cap
$5.9B
$38.4M
Price % of 52-Week High
87.62%
45.53%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.78%
1-Year Price Total Return
74.81%
-39.05%
Beta (5-Year)
0.997
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$122.47
200-day SMA
Buy
Level
$92.82
Bollinger Bands (100)
Buy
Level
86.47 - 116.59
Chaikin Money Flow
Buy
Level
63.2M
20-day SMA
Sell
Level
$126.64
Relative Strength Index (RSI14)
Buy
Level
52.03
ADX Line
Buy
Level
26.89
Williams %R
Neutral
Level
-63.0394
50-day SMA
Buy
Level
$109.75
MACD (12, 26)
Buy
Level
2.40
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
205.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.6534)
Sell
CA Score
(Annual)
Level (-3.7016)
Buy
Beneish M-Score
(Annual)
Level (-3.4597)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (4.789)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Stock Forecast FAQ
In the current month, AXSM has received 12 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AXSM average analyst price target in the past 3 months is $173.00.
-
Where Will Axsome Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Axsome Therapeutics share price will rise to $173.00 per share over the next 12 months.
-
What Do Analysts Say About Axsome Therapeutics?
Analysts are divided on their view about Axsome Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Axsome Therapeutics is a Sell and believe this share price will drop from its current level to $115.00.
-
What Is Axsome Therapeutics's Price Target?
The price target for Axsome Therapeutics over the next 1-year time period is forecast to be $173.00 according to 12 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AXSM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Axsome Therapeutics is a Buy. 12 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AXSM?
You can purchase shares of Axsome Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Axsome Therapeutics shares.
-
What Is The Axsome Therapeutics Share Price Today?
Axsome Therapeutics was last trading at $121.95 per share. This represents the most recent stock quote for Axsome Therapeutics. Yesterday, Axsome Therapeutics closed at $121.91 per share.
-
How To Buy Axsome Therapeutics Stock Online?
In order to purchase Axsome Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Reddit a Buy on the Dip?
Reddit (NYSE:RDDT) share price has been on the proverbial ropes…
Qualcomm Stock: 5G Leader at a Bargain Price?
Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
59
GRRR alert for Mar 15
Gorilla Technology Group [GRRR] is up 29.72% over the past day.
Sell
49
SMTC alert for Mar 15
Semtech [SMTC] is up 21.28% over the past day.
Buy
62
PLPC alert for Mar 15
Preformed Line Products [PLPC] is up 17.38% over the past day.
